Index - P/E - EPS (ttm) - Insider Own 31.76% Shs Outstand 42.00M Perf Week 3.78%
Market Cap 975.45M Forward P/E - EPS next Y - Insider Trans 56.58% Shs Float 28.66M Perf Month -
Income - PEG - EPS next Q -0.69 Inst Own 32.98% Short Float 1.53% Perf Quarter -
Sales - P/S - EPS this Y - Inst Trans - Short Ratio 1.21 Perf Half Y -
Book/sh - P/B - EPS next Y - ROA - Short Interest 0.44M Perf Year -
Cash/sh 3.27 P/C 7.09 EPS next 5Y - ROE - 52W Range 18.62 - 26.34 Perf YTD 8.53%
Dividend Est. - P/FCF - EPS past 5Y - ROI - 52W High -11.83% Beta -
Dividend TTM - Quick Ratio 10.08 Sales past 5Y 0.00% Gross Margin - 52W Low 24.73% ATR (14) 2.16
Dividend Ex-Date - Current Ratio 10.08 EPS Y/Y TTM - Oper. Margin - RSI (14) - Volatility 9.35% -
Employees - Debt/Eq - Sales Y/Y TTM - Profit Margin - Recom 1.00 Target Price 43.67
Option/Short No / Yes LT Debt/Eq - EPS Q/Q - Payout - Rel Volume 0.25 Prev Close 22.50
Sales Surprise 0.00% EPS Surprise 0.00% Sales Q/Q - Earnings Nov 20 BMO Avg Volume 362.29K Price 23.23
SMA20 0.52% SMA50 0.52% SMA200 0.52% Trades
Volume 6,286 Change 3.22%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-19-24 Initiated Wells Fargo
Overweight
$43
Nov-19-24 Initiated TD Cowen
Buy
Nov-19-24 Initiated JP Morgan
Overweight
$38
Nov-19-24 Initiated Cantor Fitzgerald
Overweight
$50
Nov-20-24 07:00AM
05:10AM
Oct-30-24 04:41PM
Oct-24-24 09:47PM
Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discovery powered by proprietary Native Complex PlatformTM. Its pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. The company was founded by Robert Joseph Lefkowitz, Arthur Christopoulos, Patrick Sexton, and Jeffrey T. Finer in December 2019 and is headquartered in South San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
RA CAPITAL MANAGEMENT, L.P. Director Oct 28 '24 Buy 18.00 4,170,000 75,060,000 5,523,915 Oct 30 06:12 PM Third Rock Ventures V, L.P. 10% Owner Oct 28 '24 Buy 18.00 370,500 6,669,000 6,215,591 Oct 28 04:53 PM Third Rock Ventures V, L.P. 10% Owner Oct 28 '24 Buy 18.00 279,500 5,031,000 3,152,456 Oct 28 04:53 PM
Index RUT P/E - EPS (ttm) -3.55 Insider Own 30.42% Shs Outstand 41.21M Perf Week -7.76%
Market Cap 721.72M Forward P/E - EPS next Y -4.17 Insider Trans 2.06% Shs Float 31.94M Perf Month -25.05%
Income -154.14M PEG - EPS next Q -0.99 Inst Own 81.47% Short Float 17.44% Perf Quarter -12.65%
Sales 0.00M P/S - EPS this Y 77.17% Inst Trans 20.25% Short Ratio 18.76 Perf Half Y -24.76%
Book/sh 8.72 P/B 1.80 EPS next Y -10.57% ROA -57.80% Short Interest 5.57M Perf Year 8.14%
Cash/sh 8.80 P/C 1.78 EPS next 5Y - ROE -69.81% 52W Range 13.56 - 33.92 Perf YTD -32.27%
Dividend Est. - P/FCF - EPS past 5Y - ROI -35.90% 52W High -53.77% Beta 2.21
Dividend TTM - Quick Ratio 18.95 Sales past 5Y 0.00% Gross Margin - 52W Low 15.63% ATR (14) 1.46
Dividend Ex-Date - Current Ratio 18.95 EPS Y/Y TTM - Oper. Margin 0.00% RSI (14) 31.98 Volatility 10.10% 8.15%
Employees - Debt/Eq 0.07 Sales Y/Y TTM - Profit Margin - Recom 1.00 Target Price 31.86
Option/Short No / Yes LT Debt/Eq 0.07 EPS Q/Q -2.14% Payout - Rel Volume 0.14 Prev Close 15.82
Sales Surprise - EPS Surprise 20.62% Sales Q/Q - Earnings Nov 12 AMC Avg Volume 296.99K Price 15.68
SMA20 -20.01% SMA50 -22.01% SMA200 -21.23% Trades
Volume 2,946 Change -0.88%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-22-24 Initiated H.C. Wainwright
Buy
$33
Jul-08-24 Initiated Chardan Capital Markets
Buy
$28
Jun-27-24 Initiated Piper Sandler
Overweight
$37
Dec-05-23 Initiated Truist
Buy
$34
Dec-05-23 Initiated TD Cowen
Outperform
Dec-05-23 Initiated JP Morgan
Overweight
$23
Dec-05-23 Initiated Jefferies
Buy
$28
Nov-12-24 04:05PM
Nov-05-24 04:05PM
09:23AM
Aug-16-24 08:53PM
06:50PM
04:05PM
Loading…
Aug-12-24 04:05PM
Jul-10-24 08:00AM
Jun-04-24 04:05PM
01:56PM
May-30-24 06:00AM
May-28-24 08:05AM
08:00AM
May-22-24 12:00PM
09:55AM
May-14-24 09:54PM
04:05PM
Loading…
04:05PM
Apr-15-24 04:05PM
Mar-21-24 10:53PM
04:05PM
Feb-29-24 04:01PM
Jan-03-24 08:05AM
Dec-18-23 04:04PM
(Commercial Observer)
+13.88%
Dec-13-23 10:51PM
04:05PM
Dec-11-23 07:53PM
Cargo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cell therapies for cancer patients. It is involved in evaluating its lead program, CRG-022, an autologous CD22 chimeric antigen receptor T-cell therapy candidate, in a potentially pivotal Phase 2 clinical trial in patients with large B-cell lymphoma whose disease relapsed or was refractory to CD19 CAR T-cell therapy. The company was founded by Crystal Mackall, Nancy Goodman, Louai Labanieh, and Robbie Majzner in December 2019 and is headquartered in San Carlos, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Chapman Gina President & CEO Sep 18 '24 Option Exercise 5.03 7,166 36,045 111,071 Sep 20 05:24 PM Chapman Gina President & CEO Sep 19 '24 Option Exercise 5.03 2,975 14,964 106,880 Sep 20 05:24 PM Chapman Gina President & CEO Sep 18 '24 Sale 25.09 7,166 179,775 103,905 Sep 20 05:24 PM Chapman Gina President & CEO Sep 19 '24 Sale 25.03 2,975 74,457 103,905 Sep 20 05:24 PM Radhakrishnan Anup Chief Financial Officer Sep 18 '24 Option Exercise 5.03 1,600 8,048 8,046 Sep 20 05:23 PM Radhakrishnan Anup Chief Financial Officer Sep 18 '24 Sale 25.28 1,600 40,452 6,446 Sep 20 05:23 PM ANUP RADHAKRISHNAN Officer Sep 18 '24 Proposed Sale 23.33 14,000 326,620 Sep 18 04:38 PM GINA CHAPMAN Director Sep 18 '24 Proposed Sale 23.33 75,000 1,749,750 Sep 18 04:36 PM Samsara BioCapital GP, LLC 10% Owner May 30 '24 Buy 17.00 294,000 4,998,000 4,415,689 Jun 03 09:45 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
